111 related articles for article (PubMed ID: 11231578)
1. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.
Gavioli R; Frisan T; Vertuani S; Bornkamm GW; Masucci MG
Nat Cell Biol; 2001 Mar; 3(3):283-8. PubMed ID: 11231578
[TBL] [Abstract][Full Text] [Related]
2. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.
Orlowski RZ; Eswara JR; Lafond-Walker A; Grever MR; Orlowski M; Dang CV
Cancer Res; 1998 Oct; 58(19):4342-8. PubMed ID: 9766662
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitylation and destruction of endogenous c-mycS by the proteasome: are myc boxes dispensable?
Chen L; Smith L; Accavitti-Loper MA; Omura S; Bingham Smith J
Arch Biochem Biophys; 2000 Feb; 374(2):306-12. PubMed ID: 10666312
[TBL] [Abstract][Full Text] [Related]
4. Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II.
Stavropoulou V; Xie J; Henriksson M; Tomkinson B; Imreh S; Masucci MG
Cancer Res; 2005 Feb; 65(4):1361-8. PubMed ID: 15735022
[TBL] [Abstract][Full Text] [Related]
5. A proteolytic system that compensates for loss of proteasome function.
Glas R; Bogyo M; McMaster JS; Gaczynska M; Ploegh HL
Nature; 1998 Apr; 392(6676):618-22. PubMed ID: 9560160
[TBL] [Abstract][Full Text] [Related]
6. B-Myc is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation.
Gregory MA; Xiao Q; Cornwall GA; Lutterbach B; Hann SR
Oncogene; 2000 Oct; 19(42):4886-95. PubMed ID: 11039906
[TBL] [Abstract][Full Text] [Related]
7. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
Gregory MA; Hann SR
Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
[TBL] [Abstract][Full Text] [Related]
8. Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis.
Hong X; Lei L; Glas R
J Exp Med; 2003 Jun; 197(12):1731-43. PubMed ID: 12810691
[TBL] [Abstract][Full Text] [Related]
9. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
10. Proteases, proteases and proteases for presentation.
Herberts C; Reits E; Neefjes J
Nat Immunol; 2003 Apr; 4(4):306-8. PubMed ID: 12660727
[No Abstract] [Full Text] [Related]
11. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
Princiotta MF; Schubert U; Chen W; Bennink JR; Myung J; Crews CM; Yewdell JW
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):513-8. PubMed ID: 11149939
[TBL] [Abstract][Full Text] [Related]
12. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity.
Wang EW; Kessler BM; Borodovsky A; Cravatt BF; Bogyo M; Ploegh HL; Glas R
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9990-5. PubMed ID: 10954757
[TBL] [Abstract][Full Text] [Related]
13. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
14. The NS2 protein generated by the parvovirus minute virus of mice is degraded by the proteasome in a manner independent of ubiquitin chain elongation or activation.
Miller CL; Pintel DJ
Virology; 2001 Jul; 285(2):346-55. PubMed ID: 11437668
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system.
Masucci MG
Oncogene; 2004 Mar; 23(11):2107-15. PubMed ID: 15021898
[TBL] [Abstract][Full Text] [Related]
16. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover.
Bahram F; von der Lehr N; Cetinkaya C; Larsson LG
Blood; 2000 Mar; 95(6):2104-10. PubMed ID: 10706881
[TBL] [Abstract][Full Text] [Related]
17. The LCR of EBV makes Burkitt's lymphoma endemic.
Niller HH; Salamon D; Banati F; Schwarzmann F; Wolf H; Minarovits J
Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
[TBL] [Abstract][Full Text] [Related]
18. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
19. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
20. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells.
Dantuma NP; Lindsten K; Glas R; Jellne M; Masucci MG
Nat Biotechnol; 2000 May; 18(5):538-43. PubMed ID: 10802622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
